Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 May 12;14:1192022. doi: 10.3389/fphar.2023.1192022

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2023 Sourbron and Lagae.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Proposed mechanisms of fenfluramine and its efficacy (A) Previously reported pathways are in black; mechanisms that are not yet confirmed in animal models of epilepsy are presented in orange (B) Efficacies confirmed by clinical data before the start of fenfluramine in clinical trials of epilepsy patients are presented in black; activities that were recently confirmed by clinical trials of epilepsy patients are presented in orange. For the corresponding references, please refer to the text. 5-HT, serotonin; ACTH, adrenocorticotropic hormone; ADHD, attention deficit hyperactivity disorder; GABA, γ-aminobutyric acid; GLUT, glutamine; OCD, obsessive compulsive disorder; σ1, sigma-1; SERT, serotonin transporter; SUDEP, sudden unexpected death in epilepsy.